Lund, Sweden — September 17, 2025 — Leads & Copy — Alligator Bioscience (STO:ATORX) announced the final outcome of its warrants series TO 13 exercise, which concluded on Sept. 15, 2025. A total of 9,009,774,000 TO 13 warrants were exercised for 9,009,774 new ordinary shares, representing an exercise rate of approximately 91.7%. The company will receive gross proceeds of approximately SEK 28.1 million through the exercise of TO 13.
The exercise period for TO 13 took place between Sept. 1-15, 2025, with each 1,000 warrants entitling the holder to subscribe for one new ordinary share at SEK 3.12 per share. The exercise increases the number of shares in the company by 9,009,774, from 34,803,898 to 43,813,672, and the share capital increases by SEK 7,207,819.20, from SEK 27,843,118.40 to SEK 35,050,937.60. Dilution for existing shareholders who did not exercise warrants is approximately 20.6%.
Exercised TO 13 warrants will be replaced by ordinary shares after registration with the Swedish Companies Registration Office.
Vator Securities AB served as Sole Global Coordinator and bookrunner, while Van Lanschot Kempen N.V. acted as financial advisor and Setterwalls Advokatbyrå AB as legal advisor. Vator Securities AB also acted as issuing agent for the Rights Issue.
Søren Bregenholt, CEO
E-mail: soren.bregenholt@alligatorbioscience.com
Phone: +46 (0) 46 540 82 00
For more information, please visit alligatorbioscience.com.
Source: Alligator Bioscience
